You are here

ABL001​

A Phase I, Multicenter, Open-label Study of Oral ​​ABL001 in Patients With CML or ​Ph+ ALL

A Phase I, Multicenter, Open-label Study of Oral ​​ABL001 in Patients With CML or ​Ph+ ALL

Novel Imatinib/Nilotinib Strategy Could Optimize CML Treatment

sandy craine's picture
Submitted by sandy craine on Tue, 26/05/2015 - 3:43pm
News | March 17, 2015 | Chronic Myeloid Leukemia, Hematologic Malignancies, Leukemia & Lymphoma By Cancer Network Staff A single-arm, open-label trial in Australia found that selective early switching from imatinib to nilotinib is feasible and effective in patients with chronic myeloid leukemia (CML).

News | March 17, 2015 | Chronic Myeloid Leukemia, Hematologic Malignancies, Leukemia & Lymphoma
By Cancer Network Staff
A single-arm, open-label trial in Australia found that selective early switching from imatinib to nilotinib is feasible and effective in patients with chronic myeloid leukemia (CML).

RCC Drug Axitinib Could Treat TKI-Resistant CML

sandy craine's picture
Submitted by sandy craine on Tue, 26/05/2015 - 3:33pm
News | February 17, 2015 | Chronic Myeloid Leukemia, Hematologic Malignancies, Leukemia & Lymphoma By Cancer Network Staff In a paper that shows the benefits of looking at old drugs in new ways, researchers showed that axitinib could be repurposed as a potentially effective treatment for chronic myeloid leukemia (CML) patients who develop resistance to standard tyrosine kinase inhibitors (TKIs) through a certain molecular mechanism.

News | February 17, 2015 | Chronic Myeloid Leukemia, Hematologic Malignancies, Leukemia & Lymphoma
By Cancer Network Staff

In a paper that shows the benefits of looking at old drugs in new ways, researchers showed that axitinib could be repurposed as a potentially effective treatment for chronic myeloid leukemia (CML) patients who develop resistance to standard tyrosine kinase inhibitors (TKIs) through a certain molecular mechanism.

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

sandy craine's picture
Submitted by sandy craine on Sat, 09/05/2015 - 2:23pm
L Kalmanti, S Saussele, M Lauseker, M C Müller, C T Dietz, L Heinrich, B Hanfstein, U Proetel, A Fabarius, S W Krause, S Rinaldetti, J Dengler, C Falge, E Oppliger-Leibundgut, A Burchert, A Neubauer, L Kanz, F Stegelmann, M Pfreundschuh, K Spiekermann, C Scheid, M Pfirrmann, A Hochhaus, J Hasford, R Hehlmann and for the SAKK and the German CML Study-Group.

L Kalmanti, S Saussele, M Lauseker, M C Müller, C T Dietz, L Heinrich, B Hanfstein, U Proetel, A Fabarius, S W Krause, S Rinaldetti, J Dengler, C Falge, E Oppliger-Leibundgut, A Burchert, A Neubauer, L Kanz, F Stegelmann, M Pfreundschuh, K Spiekermann, C Scheid, M Pfirrmann, A Hochhaus, J Hasford, R Hehlmann and for the SAKK and the German CML Study-Group.

Laboratory recommendations for scoring deep molecular responses following treatment for CML

sandy craine's picture
Submitted by sandy craine on Sat, 09/05/2015 - 2:16pm
N C P Cross1,2, H E White1,2, D Colomer3, H Ehrencrona4, L Foroni5, E Gottardi6, T Lange7, T Lion8, K Machova Polakova9, S Dulucq10, G Martinelli11, E Oppliger Leibundgut12, N Pallisgaard13, G Barbany14, T Sacha15, R Talmaci16, B Izzo17, G Saglio6, F Pane17,18, M C Müller19 and A Hochhaus20 Abstract Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.

N C P Cross1,2, H E White1,2, D Colomer3, H Ehrencrona4, L Foroni5, E Gottardi6, T Lange7, T Lion8, K Machova Polakova9, S Dulucq10, G Martinelli11, E Oppliger Leibundgut12, N Pallisgaard13, G Barbany14, T Sacha15, R Talmaci16, B Izzo17, G Saglio6, F Pane17,18, M C Müller19 and A Hochhaus20

Abstract
Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.

Bosutinib a Good Fourth-Line Option in CML

sandy craine's picture
Submitted by sandy craine on Wed, 06/05/2015 - 4:16pm
A small retrospective study of heavily pretreated patients with chronic myeloid leukemia (CML) found bosutinib to be a good option in the fourth-line setting.

A small retrospective study of heavily pretreated patients with chronic myeloid leukemia (CML) found bosutinib to be a good option in the fourth-line setting.

Pages